The following is a summary of “Association between incretin-based drugs and risk of cholangiocarcinoma among patients with ...

In a large population of people with diabetes, the use of GLP-1 receptor agonists was not linked to an increased risk for ...

The following is a summary of “Effects of Novel Antidiabetic Agents on Contrast-Associated Acute Kidney Injury in Diabetic Patients Undergoing Percutaneous Coronary Intervention,” published in the ...

A study has found no evidence that glucagon-like peptide 1 receptor agonist (GLP1-RA) use is associated with an increased ...

Cancer researchers found that patients on GLP-1s had significant risk reductions for 10 of 13 obesity-associated cancers.

For patients with diabetes undergoing a surgical procedure, an active perioperative glucagon-like peptide-1 receptor agonist ...

The series A fundraising is the biggest ever for a European biotech firm, according to the data provider PitchBook.

GoodRx CEO Wendy Barnes outlined the company's priorities at the 2025 JP Morgan Healthcare Conference in San Francisco.

While weight loss is a common new year's resolution for workers in the U.S., 2025 may mark the year that building weight loss ...

Semaglutide combined with automated insulin delivery enhances glucose control in type 1 diabetes, lowering insulin ...

With three meds approved for weight management and several on the way, these may make a dent in the obesity epidemic.

BMI falls short as a way to measure obesity. Doctors need to also determine whether body fat harms a person's health.